NCT02165397 · MORE INFO

Limitations, agreements, and source contact

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia · Source last updated 2021-03-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: 1. Institution/Investigator will not publish without Sponsor prior review and approval 2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Complete source fields

certain Agreement

other Details: 1. Institution/Investigator will not publish without Sponsor prior review and approval 2. Institution/Investigator will not publish until the earlier of (i) results of study are submitted for publication (ii) notification that submission of the multicenter results are no longer planned (iii) 18 months after study termination.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice